Ram Thapa

Ram Thapa

Auto-generated profile, based on publicly available information

Ram Thapa

Moffitt Cancer Center, Tampa, Florida

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
KJKhushali Jhaveri
Khushali Jhaveri
RTRam Thapa
Ram Thapa
DEDalia Ercan
Dalia Ercan
ASAditi Saha
Aditi Saha
JNJerald Noble
Jerald Noble
MJMichael D. Jain
Michael D. Jain
Purpose: Sarcopenia is a hallmark of cancer cachexia. Chimeric antigen receptor (CAR) T-cell therapy is associated with an inflammatory state that may exacerbate sarcopenia. The relationship among CAR T-cell therapy, sarcopenia, and metabolism is poorly understood. Experimental Design: In 83 patients with large B-cell lymphoma, the skeletal muscle index was measured from clinical images obtained at baseline and days 30 and 90 after therapy. Serum metabolomics (n = 57 patients) was performed in the first 4 weeks. Results: Baseline sarcopenia was present in more than half of patients and associated with shorter median overall survival than for non-sarcopenic patients (10.5 vs. 34.3 months; P = 0.006). This reduction was due to increased nonrelapse mortality with all six nonrelapse mortality events occurring in patients with baseline sarcopenia. In the first 30 days after CAR T-cell therapy, one of three patients experienced skeletal muscle loss greater than 10%. Muscle loss was associated with higher tumor burden and neurotoxicity but was not significantly associated with long-term survival. Serum metabolomics revealed an early (weeks 1–2) increase in purine metabolites, followed by a later (weeks 3–4) increase in triglyceride levels. The serum metabolite with the highest fold-increase from baseline was adipic acid, attributed to the inpatient hospital menu of jello and other tart beverages. Conclusions: Skeletal muscle loss after CAR T-cell therapy is common and is associated with fatty acid catabolism. Patients with baseline sarcopenia have poor tolerance and reduced survival. Future studies of dietary and exercise interventions may improve CAR T-cell therapy outcomes.

1 July 2025
Verified
Other
Open access
PDF file
KJKhushali Jhaveri
Khushali Jhaveri
RTRam Thapa
Ram Thapa
DEDalia Ercan
Dalia Ercan
ASAditi Saha
Aditi Saha
JNJerald Noble
Jerald Noble
MJMichael D. Jain
Michael D. Jain
Supplementary Figure S1: Survival Analysis by Baseline BMI Category.

1 July 2025
Verified
Other
Open access
PDF file
KJKhushali Jhaveri
Khushali Jhaveri
RTRam Thapa
Ram Thapa
DEDalia Ercan
Dalia Ercan
ASAditi Saha
Aditi Saha
JNJerald Noble
Jerald Noble
MJMichael D. Jain
Michael D. Jain
Supplementary Table S4: Mixed model coefficient estimates for SMI and total adipose tissue with sarcopenia status and time points.

1 July 2025
Verified
Other
Open access
PDF file
KJKhushali Jhaveri
Khushali Jhaveri
RTRam Thapa
Ram Thapa
DEDalia Ercan
Dalia Ercan
ASAditi Saha
Aditi Saha
JNJerald Noble
Jerald Noble
MJMichael D. Jain
Michael D. Jain
Supplementary Figure S3: Longitudinal Changes in Skeletal Muscle Index (SMI) Stratified by Gender and Sarcopenia Status Pre- and Post-CAR T-cell Therapy.

1 July 2025
Verified
Other
Open access
PDF file
KJKhushali Jhaveri
Khushali Jhaveri
RTRam Thapa
Ram Thapa
DEDalia Ercan
Dalia Ercan
ASAditi Saha
Aditi Saha
JNJerald Noble
Jerald Noble
MJMichael D. Jain
Michael D. Jain
Supplementary Figure 4: PFS and OS Stratified by Sarcopenia and SMI Loss Status at Day 30 and Day 90.

1 July 2025
Verified
Other
Open access
PDF file
KJKhushali Jhaveri
Khushali Jhaveri
RTRam Thapa
Ram Thapa
DEDalia Ercan
Dalia Ercan
ASAditi Saha
Aditi Saha
JNJerald Noble
Jerald Noble
MJMichael D. Jain
Michael D. Jain
Supplementary Table S2: Multivariable Cox fits with HR and 95% CI for NRM.